| Trial ID: | L6076 |
| Source ID: | NCT03602638
|
| Associated Drug: |
Sitagliptin
|
| Title: |
Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1
|
| Interventions: |
DRUG: Sitagliptin|DRUG: Acarbose
|
| Outcome Measures: |
Primary: coronary calcification score, Changes in coronary calcification score in Patients with coronary heart disease complicated with Type 2 Diabetes was measure with Computed tomography angiography. To measure the changes in coronary calcification score at 18 months., Changes from baseline in coronary calcification score at 18 months] |
|
| Sponsor/Collaborators: |
Sponsor: Chinese PLA General Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
300
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2018-10-01
|
| Completion Date: |
2020-12-01
|
| Results First Posted: |
|
| Last Update Posted: |
2018-07-27
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT03602638
|
